tirzepatide cv outcomes trial cardiovascular glp #tizepatide #semaglutide #naturemedicine #aha25 Tirzepatide and Cardiovascular Outcomes in

The Zepbound prescribing label includes an identical caution about gastric emptying and oral drug absorption as the Wegovy label

Tolerance and dose adjustment over time Some people report decreasing effectiveness at a given dose after 6-12 months

Successful maintenance therapy is typically a combination of medication support, balanced nutrition, physical activity, and continuous monitoring

Do not take Tirzepatide if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Although our treatments can deliver long-lasting results, factors such as genetics and lifestyle may influence their recurrence